Latest & greatest articles for adhd Methylphenidate

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adhd Methylphenidate or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adhd Methylphenidate and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for adhd Methylphenidate

1. Continued Benefits of Methylphenidate in ADHD After 2 Years in Clinical Practice: A Randomized Placebo-Controlled Discontinuation Study (Abstract)

Continued Benefits of Methylphenidate in ADHD After 2 Years in Clinical Practice: A Randomized Placebo-Controlled Discontinuation Study The benefits of long-term use of methylphenidate treatment in children and adolescents with attention deficit hyperactivity disorder (ADHD), as frequently prescribed in clinical practice, are unclear. The authors investigated whether methylphenidate remains beneficial after 2 years of use.Ninety-four children and adolescents (ages 8-18 years) who had been (...) . The ADHD-RS inattention subscale and the CTRS-R:S ADHD index and hyperactivity subscale also deteriorated significantly more in the discontinuation group. The CGI-I indicated worsening in 40.4% of the discontinuation group, compared with 15.9% of the continuation group.Continued treatment with methylphenidate remains effective after long-term use. Some individual patients may, however, be withdrawn from methylphenidate without deterioration. This finding supports guideline recommendations that patients

2019 EvidenceUpdates

2. Psychosis with Methylphenidate or Amphetamine in Patients with ADHD. Full Text available with Trip Pro

Psychosis with Methylphenidate or Amphetamine in Patients with ADHD. The prescription use of the stimulants methylphenidate and amphetamine for the treatment of attention deficit-hyperactivity disorder (ADHD) has been increasing. In 2007, the Food and Drug Administration mandated changes to drug labels for stimulants on the basis of findings of new-onset psychosis. Whether the risk of psychosis in adolescents and young adults with ADHD differs among various stimulants has not been extensively (...) studied.We used data from two commercial insurance claims databases to assess patients 13 to 25 years of age who had received a diagnosis of ADHD and who started taking methylphenidate or amphetamine between January 1, 2004, and September 30, 2015. The outcome was a new diagnosis of psychosis for which an antipsychotic medication was prescribed during the first 60 days after the date of the onset of psychosis. To estimate hazard ratios for psychosis, we used propensity scores to match patients who

2019 NEJM

3. Methylphenidate extended-release oral suspension for the treatment of attention-deficit/hyperactivity disorder: a practical guide for pharmacists Full Text available with Trip Pro

Methylphenidate extended-release oral suspension for the treatment of attention-deficit/hyperactivity disorder: a practical guide for pharmacists Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental condition that affects children, adolescents, and adults worldwide. The purpose of this review was to inform pharmacists of the numerous options to treat ADHD, with a focus on one of the more recently approved formulations, methylphenidate extended-release oral suspension (MEROS (...) ). Symptoms of ADHD can negatively impact an individual's health and quality of life and impair function in multiple settings. Psychostimulants such as methylphenidate- and amphetamine-based agents are first-line pharmacologic treatments for ADHD. However, there are multiple formulations, including immediate release (administered two to three times/day), solid extended release (ER), or transdermal patch. MEROS is a once daily, long-acting liquid preparation that has demonstrated favorable safety

2017 Integrated pharmacy research & practice

4. Effectiveness of methylphenidate and PUFA for the treatment of patients with ADHD: A double-blinded randomized clinical trial Full Text available with Trip Pro

Effectiveness of methylphenidate and PUFA for the treatment of patients with ADHD: A double-blinded randomized clinical trial In some children with ADHD, sub-optimal levels of various nutrients including PUFA especially omega-3 has been observed, and contradictory reports exist on the results of studies conducted on the positive therapeutic effects of PUFA in patients with ADHD.The aim of this study was to investigate the effectiveness of methylphenidate and PUFA on treatment of patients (...) with ADHD in Zahedan, Iran.In this clinical trial, 40 children between 6 and 12 years of age with ADHD were investigated in Zahedan in 2014. Patients were randomly divided into two groups of methylphenidate plus PUFA and methylphenidate plus placebo. ADHD rating scale was filled before and after the study for patients of both groups. Finally, data were analyzed using SPSS18, paired-samples t-test and chi-square.Mean age of patients was 2.9±1.8 years. Thirty-three children (82.5%) were boys and seven

2017 Electronic physician Controlled trial quality: uncertain

5. The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder

The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder Kim Boesen , Luis Carlos Saiz , Juan Erviti , Ole Jakob Storebø , Christian Gluud , Peter C Gøtzsche , Karsten Juhl Jørgensen Statistics from Altmetric.com Background Attention deficit hyperactivity disorder (ADHD) in adults is one of the most controversial diagnoses in medicine, and the use of methylphenidate is sharply rising. The Cochrane review by Epstein and colleagues about (...) The trials lasted only 1–7 weeks, and the long-term beneficial and harmful effects of methylphenidate are therefore unknown. Most adults with ADHD receive methylphenidate for substantially longer periods, and the beneficial effects may furthermore diminish over time. This was observed in the large Multimodal Treatment of Attention Deficit Hyperactivity Disorder Study in children. The short trial duration should therefore have led to additional downgrading for indirectness according to GRADE. Small trials

2017 Evidence-Based Medicine

6. Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. Full Text available with Trip Pro

Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study.  To determine whether treatment with methylphenidate in children and young people with attention-deficit/hyperactivity disorder (ADHD) was associated with cardiovascular events. Self controlled case series analysis. Nationwide health insurance database, 1 January 2008 to 31 December 2011, in South Korea. 1224 patients aged (...) in the early risk periods between eight and 56 days after the start of treatment with methylphenidate. No significant increased risk was observed for hypertension, ischemic stroke, or heart failure. The relative risk of myocardial infarction and arrhythmias is increased in the early period after the start of methylphenidate treatment for ADHD in children and young people. Though the absolute risk is likely to be low, the risk-benefit balance of methylphenidate should be carefully considered, particularly

2016 BMJ

7. Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater Full Text available with Trip Pro

Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater Article Text Perspective Methylphenidate for ADHD in children and adolescents: throwing the baby out

2016 Evidence-Based Mental Health

8. Evidence on methylphenidate in children and adolescents with ADHD is in fact of ?very low quality?

Evidence on methylphenidate in children and adolescents with ADHD is in fact of ?very low quality? Evidence on methylphenidate in children and adolescents with ADHD is in fact of ‘very low quality’ | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Evidence on methylphenidate in children and adolescents with ADHD is in fact of ‘very low quality’ Article Text Perspective Evidence on methylphenidate in children and adolescents with ADHD

2016 Evidence-Based Mental Health

9. Duration of Dosage Effect for Methylphenidate SR and Dextroamphetamine SR for Patients with Attention Deficit Hyperactivity Disorder

identified regarding the duration of dosage effect for methylphenidate SR for patients with attention deficit hyperactivity disorder. Tags attention deficit disorder with hyperactivity, dexamfetamine, dexedrine, dextroamphetamine, mental health, methylphenidate, ritalin, Concerta, time course Files Rapid Response Summary of Abstracts Published : September 2, 2015 Related Content Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter: (...) Duration of Dosage Effect for Methylphenidate SR and Dextroamphetamine SR for Patients with Attention Deficit Hyperactivity Disorder Duration of Dosage Effect for Methylphenidate SR and Dextroamphetamine SR for Patients with Attention Deficit Hyperactivity Disorder | CADTH.ca Find the information you need Duration of Dosage Effect for Methylphenidate SR and Dextroamphetamine SR for Patients with Attention Deficit Hyperactivity Disorder Duration of Dosage Effect for Methylphenidate SR

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

10. Methylphenidate reduces ADHD symptoms in children with severe ADHD and intellectual disability

and intellectual disability Statistics from Altmetric.com Question Question: Are stimulants safe and effective for the treatment of children with attention deficit hyperactivity disorder (ADHD) and intellectual disability? Patients: 122 children and adolescents (aged 7 years; 85% male) with ADHD (International Classification of Disease-10 diagnosis of hyperkinetic disorder) and intellectual disability (IQ 30–69). Recruitment was through clinical referrals and community screening (using the Special Education (...) Methylphenidate reduces ADHD symptoms in children with severe ADHD and intellectual disability Methylphenidate reduces ADHD symptoms in children with severe ADHD and intellectual disability | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts

2013 Evidence-Based Mental Health

11. Review: methylphenidate and atomoxetine have similar efficacy and acceptability in children and adolescents with ADHD

: methylphenidate and atomoxetine have similar efficacy and acceptability in children and adolescents with ADHD Statistics from Altmetric.com Question Question: Is methylphenidate (MPH) or atomoxetine superior to the treatment of children and adolescents with attention deficit hyperactivity disorder (ADHD)? Outcomes: Symptoms (assessed on the ADHDRS-IV Parent: Inv and Turgay DSM-IV-Based Child and Adolescent Behaviour Disorders Screening and Rating Scale (T-DSM-IV-S)); response (as defined in the individual (...) Review: methylphenidate and atomoxetine have similar efficacy and acceptability in children and adolescents with ADHD Review: methylphenidate and atomoxetine have similar efficacy and acceptability in children and adolescents with ADHD | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your

2012 Evidence-Based Mental Health

12. [Efficacy of atomoxetine and methylphenidate in attention deficits hyperactivity disorder in adults: a rapid review]

these two medications for adult ADHD is considered appropriate. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Adrenergic Uptake Inhibitors; Adult; Attention Deficit Disorder with Hyperactivitys; Methylphenidate; Propylamines Language Published Korean Country of organisation South Korea English summary An English language summary is available. Address for correspondence National Evidence-based Healthcare Collaborating Agency (NECA), Changkyung B/D 9F, Wonnam-dong 28-7 (...) [Efficacy of atomoxetine and methylphenidate in attention deficits hyperactivity disorder in adults: a rapid review] [Efficacy of atomoxetine and methylphenidate in attention deficits hyperactivity disorder in adults: a rapid review] [Efficacy of atomoxetine and methylphenidate in attention deficits hyperactivity disorder in adults: a rapid review] Jang BH, Lee HY, Jung YJ, An JH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA

2012 Health Technology Assessment (HTA) Database.

13. Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis

Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

14. OROS methylphenidate (Concerta) for the treatment of children and adults with ADHD

RE, Mestas R et al. A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. Journal of Clinical Psychiatry 2007; 68: 93-101. Stein MA et al. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2003; 112: 404. Swanson J et al. Development of a new once-a-day formulation of methylphenidate (...) . www.FdaAdvisoryCommittee.com/FDC/Advisory_Committee/ U.S. FDA NDA 21-121 Concerta Medical Review. Avail at www.fda.gov/cder Wilens T, McBurnett K, Stein M, Lerner M et al. ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study. Journal of the Academy of Child and Adolescent Pyschiatry 2005; 44(10): 1015-1023. Wilens TE et al. Multisite controlled study of OROS MPH in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 2006; 160

2010 Therapeutics Letter

15. Should a child with ADHD and epilepsy be given Ritalin?

with epilepsy and ADHD] does [methylphenidate (MPH)compared with placebo or no MPH] increase [the number of seizures]? Clinical Scenario A 10-year-old boy with well controlled epilepsy on sodium valproate attends your clinic. On a previous clinic visit his mother complained that he was hyperactive, impulsive and could not concentrate. This was affecting his school work. You sent Conners' Questionnaires to his parents and the school, and asked the attention deficit hyperactivity disorder (ADHD) nurse (...) . The Ovid Medline and EMBASE databases were also searched. MeSH words used were: ‘Methyphenidate’, ‘Epilepsy’, ‘Attention deficit disorder’. Keywords used were: ‘ADHD, attention deficit, attention deficit disorder’, ‘Epilepsy, seizure, fit’ and ‘Methylphenidate, Ritalin’. Limits were: English language and human. Search Outcome The Medline search revealed 13 results, of which three were potentially relevant. The EMBASE search revealed 34 results, of which six were potentially relevant. The remaining

2010 BestBETS

16. Review: Methylphenidate and psychosocial treatments either alone or in combination reduce ADHD symptoms

treatments either alone or in combination reduce ADHD symptoms Statistics from Altmetric.com QUESTION Question: How effective are short-acting methylphenidate and psychosocial treatments, alone or in combination, for school-aged children with attention deficit hyperactivity disorder (ADHD)? Outcomes: Core ADHD or oppositional defiant disorder/conduct disorder (ODD/CD) symptoms, social behaviour and academic functioning. METHODS Design: Systematic review with meta-analysis. Data sources: PubMed, PsychInfo (...) Review: Methylphenidate and psychosocial treatments either alone or in combination reduce ADHD symptoms Review: Methylphenidate and psychosocial treatments either alone or in combination reduce ADHD symptoms | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password

2009 Evidence-Based Mental Health

17. Osmotically released methylphenidate is more effective than atomoxetine in children and adolescents with ADHD

methylphenidate is more effective than atomoxetine in children and adolescents with ADHD Statistics from Altmetric.com QUESTION Question: Is osmotically released methylphenidate more effective than atomoxetine or placebo in children and adolescents with attention deficit hyperactivity disorder (ADHD)? Patients: 516 children and adolescents with DSM-IV ADHD (aged 6–16 years; 26% female, mean age 10.2 years). Exclusions: ADHD symptom severity <1.5 standard deviations above average on the ADHD Rating Scale IV (...) Osmotically released methylphenidate is more effective than atomoxetine in children and adolescents with ADHD Osmotically released methylphenidate is more effective than atomoxetine in children and adolescents with ADHD | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username

2009 Evidence-Based Mental Health

18. Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder

Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

19. Attention deficit hyperactivity disorder in children: comparative efficacy of traditional Chinese medicine and methylphenidate

to methylphenidate may not be reliable. Implications of the review for practice and research Practice : The authors did not state any implications for practice. Research : The authors indicated that more high-quality trials of traditional Chinese medicine for treatment of children with ADHD were needed. Funding Not stated. Bibliographic details Lan Y, Zhang LL, Luo R. Attention deficit hyperactivity disorder in children: comparative efficacy of traditional Chinese medicine and methylphenidate. Journal (...) Attention deficit hyperactivity disorder in children: comparative efficacy of traditional Chinese medicine and methylphenidate Attention deficit hyperactivity disorder in children: comparative efficacy of traditional Chinese medicine and methylphenidate Attention deficit hyperactivity disorder in children: comparative efficacy of traditional Chinese medicine and methylphenidate Lan Y, Zhang LL, Luo R CRD summary This review identified trials of traditional Chinese medicine compared

2009 DARE.

20. A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain Full Text available with Trip Pro

(both immediate and extended release) or no treatment, in Spanish children with attention deficit hyperactivity disorder (ADHD). Interventions Methylphenidate, a mild stimulant and the most common treatment for children with ADHD, was compared with atomoxetine, a new non-stimulant alternative, in Spain. The study also compared no medication to capture those patients who could not receive stimulant medication due to a previous adverse experience or co-morbidities. Three populations were evaluated (...) A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain Hong J, Dilla T, Arellano

2009 NHS Economic Evaluation Database.